Table 1 Clinical characteristics of the patients with rheumatoid arthritis a from the discovery collection
Features | All patients | Infliximab | Adalimumab |
|---|---|---|---|
Patients, number (%)a | 205 | 151 (73.7) | 54 (26.3) |
Female (%) | 83.4 | 85.4 | 77.8 |
Age at diagnosis, median (IQR) | 47 (38 to 55) | 47 (37 to 55) | 48 (40 to 56) |
Diagnosis to anti-TNF, median (IQR) | 6 (3 to 12) | 6 (3 to 12) | 6 (2 to 11) |
RF, % | 74.5 | 74.7 | 74.1 |
ACPA, % | 75.7 | 75.4 | 76.9 |
Erosive arthritis, % | 84.9 | 83.5 | 88.9 |
Smoking, % | 13.9 | 11.8 | 20.0 |
DMARDs before anti-TNF, mean ± SD | 2.5 ± 1.2 | 2.5 ± 1.2 | 2.6 ± 1.1 |
Concomitant DMARDs (%) | 97.5 | 98.0 | 96.3 |
Baseline ESR, median (IQR)b | 34 (19 to 54) | 34 (19 to 53) | 34 (19 to 57) |
Baseline CRP (mg/L), median (IQR)b | 11.5 (5.5 to 23.9) | 11.5 (5.5 to 23.9) | 14.3 (5.5 to 23) |
Baseline HAQ, median (IQR)b | 1.5 (1.0 to 2.0) | 1.5 (1.0 to 2.0) | 1.4 (1.0 to 2.0) |
DAS28, (mean ± SD) | |||
baseline | 5.9 ± 1.2 | 5.9 ± 1.1 | 5.9 ± 1.4 |
three months | 3.9 ± 1.4 | 4.0 ± 1.5 | 3.5 ± 1.1 |
six months | 3.8 ± 1.4 | 4.0 ± 1.5 | 3.4 ± 1.2 |
twelve months | 3.7 ± 1.5 | 3.8 ± 1.5 | 3.4 ± 1.6 |
EULAR response, % | |||
three months | |||
responder | 30.4 | 28.7 | 34.6 |
moderate | 50.8 | 50.4 | 51.9 |
no-responder | 18.8 | 20.9 | 13.5 |
six months | |||
responder | 32.8 | 32.1 | 34.8 |
moderate | 43.5 | 40.7 | 52.2 |
no-responder | 23.7 | 27.1 | 13.0 |
twelve months | |||
responder | 43.5 | 40.2 | 51.1 |
moderate | 35.1 | 40.2 | 23.4 |
no-responder | 21.4 | 19.6 | 25.5 |